<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>22(1)</volume><submitter>Sinn K</submitter><pubmed_abstract>&lt;h4>Purpose&lt;/h4>The prognostic value of pretreatment and preoperative fibrinogen plasma levels and the modified Glasgow prognostic score (mGPS) in stage III/N2 non-small cell lung cancer (NSCLC) patients who receive neoadjuvant treatment followed by radical surgery is yet unclear.&lt;h4>Methods&lt;/h4>Fibrinogen levels and mGPS of 84 patients with initial stage III/N2 NSCLC, who received neoadjuvant therapy followed by complete surgical resection from 2002 to 2014 were retrospectively analyzed and correlated with clinical parameters and overall survival (OS). Data were analyzed using log-rank and Cox regression analysis adjusted for clinical and pathological factors.&lt;h4>Results&lt;/h4>Median serum fibrinogen level after neoadjuvant treatment was 439 mg/dL (IQR 158 mg/dL). Elevated fibrinogen levels</pubmed_abstract><journal>BMC cancer</journal><pagination>1197</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9675967</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Impact of fibrinogen levels and modified Glasgow prognostic score on survival of stage III/N2 non-small cell lung cancer patients treated with neoadjuvant therapy and radical resection.</pubmed_title><pmcid>PMC9675967</pmcid><pubmed_authors>Klepetko W</pubmed_authors><pubmed_authors>Grusch M</pubmed_authors><pubmed_authors>Hoda MA</pubmed_authors><pubmed_authors>Hoetzenecker K</pubmed_authors><pubmed_authors>Klikovits T</pubmed_authors><pubmed_authors>Sinn K</pubmed_authors><pubmed_authors>Mosleh B</pubmed_authors><pubmed_authors>Gompelmann D</pubmed_authors></additional><is_claimable>false</is_claimable><name>Impact of fibrinogen levels and modified Glasgow prognostic score on survival of stage III/N2 non-small cell lung cancer patients treated with neoadjuvant therapy and radical resection.</name><description>&lt;h4>Purpose&lt;/h4>The prognostic value of pretreatment and preoperative fibrinogen plasma levels and the modified Glasgow prognostic score (mGPS) in stage III/N2 non-small cell lung cancer (NSCLC) patients who receive neoadjuvant treatment followed by radical surgery is yet unclear.&lt;h4>Methods&lt;/h4>Fibrinogen levels and mGPS of 84 patients with initial stage III/N2 NSCLC, who received neoadjuvant therapy followed by complete surgical resection from 2002 to 2014 were retrospectively analyzed and correlated with clinical parameters and overall survival (OS). Data were analyzed using log-rank and Cox regression analysis adjusted for clinical and pathological factors.&lt;h4>Results&lt;/h4>Median serum fibrinogen level after neoadjuvant treatment was 439 mg/dL (IQR 158 mg/dL). Elevated fibrinogen levels</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Nov</publication><modification>2025-04-18T22:30:07.556Z</modification><creation>2025-04-07T10:14:39.981Z</creation></dates><accession>S-EPMC9675967</accession><cross_references><pubmed>36403011</pubmed><doi>10.1186/s12885-022-10298-9</doi></cross_references></HashMap>